Nuvectis Pharma, Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this is an annual filing; the provided financial statements report full-year results, not standalone fourth-quarter figures.
Business context
Nuvectis is a clinical-stage oncology biopharmaceutical company developing precision medicines for genetically defined patient populations. It had no approved products and generated no product revenue. Its lead candidate, NXP800, was in Phase 1 dose escalation; NXP900 remained preclinical, with an IND submission and Phase 1a start targeted for the first half of 2023. The FDA granted NXP800 Fast Track Designation in December 2022 for platinum-resistant, ARID1a-mutated ovarian carcinoma; this designation is not regulatory approval.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $13.227 million | $9.545 million |
| General and administrative expense | $6.007 million | $3.349 million |
| Operating loss | $19.234 million | $12.894 million |
| Net loss | $19.085 million | $12.890 million |
| Basic and diluted loss per share | $1.51 | $3.02 |
| Net cash used in operating activities | $13.559 million | $9.504 million |
FY2022 finance income was $149,000. Cash and cash equivalents were $19.993 million at year-end, versus $5.742 million a year earlier. Current assets were $20.405 million and current liabilities $6.186 million. The company reported no debt; its assets consisted primarily of cash and cash equivalents. Accumulated deficit was $31.985 million. Profit margins are not meaningful because the company had no revenue.
Changes and financing
- R&D expense increased $3.682 million year over year, reflecting higher employee, clinical-trial and manufacturing costs; FY2022 also included $2.297 million of license fees. G&A increased $2.658 million, including professional services, compensation and $1.183 million of insurance expense.
- Net loss increased $6.195 million, while loss per share narrowed, principally alongside a higher weighted-average share count following the IPO and other equity issuance.
- The February 2022 IPO generated approximately $13.6 million in net proceeds; the July 2022 private placement generated approximately $14.3 million net. Net cash from financing activities was $27.810 million.
- Common shares outstanding were 14,642,483 at December 31, 2022 and 14,752,403 as of March 1, 2023. The July placement also included investment options and warrants, creating potential future dilution. In February 2023, the company reported approximately $660,000 of proceeds from exercise of IPO underwriter warrants and approximately $39,000 from exercise of investment options.
Outlook, risks and unusual items
Management expected year-end cash to fund planned operations for more than 12 months from issuance of the financial statements, but stated that additional capital will be needed to complete clinical development and pursue regulatory approvals. This runway estimate depends on assumptions that may prove incorrect. Management expected R&D and G&A costs to rise as programs advance.
- Development remains early-stage: NXP800’s Phase 1b expansion was expected to begin in the first half of 2023, while NXP900’s IND submission and Phase 1a study were also planned for that period. These were plans, not assured milestones.
- The company relies on third parties and single-source manufacturers for drug substance and finished product. Manufacturing, trial enrollment, safety or efficacy results, regulatory review and access to capital could delay or halt development.
- License agreements include contingent milestone obligations: NXP800 had up to $22.0 million in remaining pre-approval milestones and up to $178 million in regulatory and commercial milestones, plus tiered royalties; NXP900 had up to $45.5 million in remaining pre-approval milestones and up to $279.5 million in regulatory and commercial milestones, plus tiered royalties. These amounts are contingent on future events and were not accrued as liabilities at year-end.
- The company reported no material legal matters and no recognized contingent liabilities at year-end. COVID-19 was not considered to have a material influence on accounting estimates, though operational effects remained uncertain.
- The audited financial statements received an unqualified opinion. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Whether cash use and the stated runway remain consistent with actual trial, manufacturing and operating costs, and when additional financing may be required.
- Progress and reported safety, tolerability and efficacy data for NXP800, including whether the planned Phase 1b study began on schedule; confirm NXP900’s IND and clinical-trial status.
- Current share count and potential dilution from outstanding options, warrants and other equity awards.
- The terms, timing and contingencies of license milestones, royalties and research-support commitments, including any amounts paid or remaining.
- Whether sole-source manufacturers can supply clinical material on time and to required quality standards.